• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

二次打击?肺动脉高压、突变与处方苯丙胺类药物暴露。

A second hit? Pulmonary arterial hypertension, mutation, and exposure to prescription amphetamines.

作者信息

Jaliawala Huzaifa A, Parmar Miloni, Summers Katherine, Bernardo Roberto J

机构信息

Division of Pulmonary, Critical Care and Sleep Medicine University of Oklahoma Health Sciences Center Oklahoma City Oklahoma USA.

Department of Internal Medicine University of Oklahoma Health Sciences Center Oklahoma City Oklahoma USA.

出版信息

Pulm Circ. 2022 Mar 14;12(1):e12053. doi: 10.1002/pul2.12053. eCollection 2022 Jan.

DOI:10.1002/pul2.12053
PMID:35506068
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9052970/
Abstract

The second hit hypothesis in pulmonary hypertension refers to the development of pulmonary vascular disease in individuals at risk, after an additional exposure or "hit" to factors with potential injury to the pulmonary circulation, such as drugs or toxins. We here present a case of severe pulmonary hypertension diagnosed during the third trimester of pregnancy, in a patient with familial history of pulmonary hypertension, found to have a heterozygous mutation in the gene, who also had chronic exposure to prescription amphetamines. We hypothesize that exposure to prescription amphetamines could act as a second hit of pulmonary vascular injury in individuals at risk of pulmonary vascular disease.

摘要

肺动脉高压中的二次打击假说指的是,有肺动脉高压风险的个体,在受到另外一种对肺循环有潜在损伤的因素(如药物或毒素)的暴露或“打击”后,发生肺血管疾病。我们在此报告一例在妊娠晚期诊断出严重肺动脉高压的病例,该患者有肺动脉高压家族史,基因检测发现杂合突变,且长期接触处方类苯丙胺。我们推测,接触处方类苯丙胺可能会成为有肺血管疾病风险个体肺血管损伤的二次打击因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6917/9052970/8665ab292b05/PUL2-12-e12053-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6917/9052970/8665ab292b05/PUL2-12-e12053-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6917/9052970/8665ab292b05/PUL2-12-e12053-g001.jpg

相似文献

1
A second hit? Pulmonary arterial hypertension, mutation, and exposure to prescription amphetamines.二次打击?肺动脉高压、突变与处方苯丙胺类药物暴露。
Pulm Circ. 2022 Mar 14;12(1):e12053. doi: 10.1002/pul2.12053. eCollection 2022 Jan.
2
Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation.表型沉默的骨形态发生蛋白受体 2 突变通过增加新生内膜转化的风险使大鼠易患炎症诱导的肺动脉高压。
Circulation. 2019 Oct 22;140(17):1409-1425. doi: 10.1161/CIRCULATIONAHA.119.040629. Epub 2019 Aug 29.
3
BMPRII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators.骨形态发生蛋白受体II(BMPRII)影响肺微血管内皮细胞对炎症介质的反应。
Pflugers Arch. 2016 Nov;468(11-12):1969-1983. doi: 10.1007/s00424-016-1899-1. Epub 2016 Nov 6.
4
Mutation in BMPR2 Promoter: A 'Second Hit' for Manifestation of Pulmonary Arterial Hypertension?骨形态发生蛋白受体2(BMPR2)启动子突变:肺动脉高压表现的“二次打击”?
PLoS One. 2015 Jul 13;10(7):e0133042. doi: 10.1371/journal.pone.0133042. eCollection 2015.
5
Investigation of second genetic hits at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension.对骨形态发生蛋白受体 2(BMPR2)基因座的第二次遗传打击作为家族性肺动脉高压疾病进展调节因子的研究。
Circulation. 2005 Feb 8;111(5):607-13. doi: 10.1161/01.CIR.0000154543.07679.08.
6
Synergistic heterozygosity for TGFbeta1 SNPs and BMPR2 mutations modulates the age at diagnosis and penetrance of familial pulmonary arterial hypertension.转化生长因子β1单核苷酸多态性(TGFbeta1 SNPs)与骨形态发生蛋白受体2(BMPR2)突变的协同杂合性调节家族性肺动脉高压的诊断年龄和外显率。
Genet Med. 2008 May;10(5):359-65. doi: 10.1097/GIM.0b013e318172dcdf.
7
Increased susceptibility to hypoxic pulmonary hypertension in Bmpr2 mutant mice is associated with endothelial dysfunction in the pulmonary vasculature.Bmpr2突变小鼠对缺氧性肺动脉高压的易感性增加与肺血管内皮功能障碍有关。
Am J Physiol Lung Cell Mol Physiol. 2008 Jan;294(1):L98-109. doi: 10.1152/ajplung.00034.2007. Epub 2007 Nov 16.
8
Screening for pulmonary arterial hypertension in adults carrying a mutation.筛查携带突变的成年人中的肺动脉高压。
Eur Respir J. 2021 Jul 22;58(1). doi: 10.1183/13993003.04229-2020. Print 2021 Jul.
9
BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension.BMPR2 突变状态影响肺动脉高压中的支气管血管变化。
Eur Respir J. 2016 Dec;48(6):1668-1681. doi: 10.1183/13993003.00464-2016. Epub 2016 Nov 3.
10
Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice.杂合子BMPR2突变小鼠中的炎症、内皮损伤和持续性肺动脉高压。
Am J Physiol Heart Circ Physiol. 2008 Aug;295(2):H677-90. doi: 10.1152/ajpheart.91519.2007. Epub 2008 Jun 13.

引用本文的文献

1
Pulmonary Hypertension Induced by Right Pulmonary Artery Occlusion: Hemodynamic Consequences of Mutation.右肺动脉闭塞引起的肺动脉高压:突变的血液动力学后果。
J Am Heart Assoc. 2024 Jul 16;13(14):e034621. doi: 10.1161/JAHA.124.034621. Epub 2024 Jul 9.
2
Characteristics and outcomes of gemcitabine-associated pulmonary hypertension.吉西他滨相关性肺动脉高压的特征与转归
ERJ Open Res. 2024 May 20;10(3). doi: 10.1183/23120541.00654-2023. eCollection 2024 May.
3
Human iPSCs as Model Systems for BMP-Related Rare Diseases.人诱导多能干细胞作为 BMP 相关罕见病的模型系统。

本文引用的文献

1
Screening for pulmonary arterial hypertension in adults carrying a mutation.筛查携带突变的成年人中的肺动脉高压。
Eur Respir J. 2021 Jul 22;58(1). doi: 10.1183/13993003.04229-2020. Print 2021 Jul.
2
Mechanics of right ventricular dysfunction in pulmonary arterial hypertension and heart failure with preserved ejection fraction.肺动脉高压和射血分数保留的心力衰竭中右心室功能障碍的机制。
Cardiovasc Diagn Ther. 2020 Oct;10(5):1580-1603. doi: 10.21037/cdt-20-479.
3
Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation.
Cells. 2023 Sep 2;12(17):2200. doi: 10.3390/cells12172200.
4
Genetic counselling and testing in pulmonary arterial hypertension: a consensus statement on behalf of the International Consortium for Genetic Studies in PAH.肺动脉高压的遗传咨询和检测:国际肺动脉高压遗传研究联盟的共识声明。
Eur Respir J. 2023 Feb 23;61(2). doi: 10.1183/13993003.01471-2022. Print 2023 Feb.
表型沉默的骨形态发生蛋白受体 2 突变通过增加新生内膜转化的风险使大鼠易患炎症诱导的肺动脉高压。
Circulation. 2019 Oct 22;140(17):1409-1425. doi: 10.1161/CIRCULATIONAHA.119.040629. Epub 2019 Aug 29.
4
Genetics and genomics of pulmonary arterial hypertension.肺动脉高压的遗传学和基因组学。
Eur Respir J. 2019 Jan 24;53(1). doi: 10.1183/13993003.01899-2018. Print 2019 Jan.
5
Features and Outcomes of Methamphetamine-associated Pulmonary Arterial Hypertension.与甲基苯丙胺相关的肺动脉高压的特征和结果。
Am J Respir Crit Care Med. 2018 Mar 15;197(6):788-800. doi: 10.1164/rccm.201705-0943OC.
6
Statement on pregnancy in pulmonary hypertension from the Pulmonary Vascular Research Institute.肺血管研究所关于肺动脉高压患者妊娠的声明。
Pulm Circ. 2015 Sep;5(3):435-65. doi: 10.1086/682230.
7
Drug-induced pulmonary arterial hypertension: a recent outbreak.药物性肺动脉高压:最近的一次爆发。
Eur Respir Rev. 2013 Sep 1;22(129):244-50. doi: 10.1183/09059180.00003313.
8
Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization.SU5416 和卵清蛋白免疫诱导的严重肺动脉高压。
Am J Respir Cell Mol Biol. 2012 Nov;47(5):679-87. doi: 10.1165/rcmb.2012-0077OC. Epub 2012 Jul 27.
9
Pulmonary arterial hypertension in an adolescent treated with methylphenidate.一名接受哌甲酯治疗的青少年的肺动脉高压
J Child Adolesc Psychopharmacol. 2010 Jun;20(3):229-31. doi: 10.1089/cap.2009.0095.
10
Amphetamine analogs increase plasma serotonin: implications for cardiac and pulmonary disease.苯丙胺类似物会增加血浆血清素:对心脏和肺部疾病的影响。
J Pharmacol Exp Ther. 2006 Aug;318(2):604-10. doi: 10.1124/jpet.106.101618. Epub 2006 Apr 27.